top of page
GLOBAL BIOSCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & DEALS. BILLIONS IN VALUE.
Sage Group News
Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice
Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquir
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo DENVER, CO / ACCESS Newswire / December 15, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a
Serpin Pharma Partners with Dogwood Therapeutics to Develop and Commercialize SP16 as a Treatment for Cancer-Related Pain
Manassas, VA - Serpin Pharma is pleased to announce a strategic partnership with Dogwood Therapeutics to develop and commercialize SP16,...
Sage Group Advises Fabre-Kramer Pharma on Partnering Deal with Aytu Biopharma for EXXUA(TM), a Newly Approved and Innovative Treatment for Major Depressive Disorder
Aytu BioPharma Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics,...
bottom of page